Glioblastoma Therapeutics Network (GTN; U19 Clinical Trial Required)
This grant funds collaborative teams to develop and clinically test new or repurposed drugs that cross the blood-brain barrier to improve adult glioblastoma treatment.
Funder: National Institutes of Health (NIH)
Due Dates: May 27, 2026 (Estimated, forecasted opportunity)
Funding Amounts: Award size not specified; cooperative agreement; multi-year, multi-project funding expected
Summary: Supports collaborative research teams to develop and clinically test novel therapies for adult glioblastoma, focusing on agents that cross the blood-brain barrier.
Key Information: Forecasted opportunity—dates and details subject to change; check program page for updates.
Description
This funding opportunity, issued by the National Cancer Institute (NCI) at NIH, aims to establish a Glioblastoma Therapeutics Network (GTN) to accelerate the development and clinical testing of novel therapies for adult glioblastoma (GBM). The program supports highly collaborative, cross-disciplinary teams capable of advancing therapeutic agents from late pre-clinical development, through IND-enabling studies, and into early-phase (Phase 0/1) clinical trials. Eligible projects may focus on either novel agents or repurposed drugs/combinations (approved for other indications) that have undergone appropriate preclinical evaluation for GBM.
The initiative seeks to bridge the translational gap in GBM drug development, particularly for agents that can cross the blood-brain barrier, with the ultimate goal of improving outcomes for adults with GBM. Successful early-stage trials funded through this mechanism are expected to transition seamlessly to later-stage clinical trials via established NCI mechanisms.
